top of page

supporting targeted treatment
genialis is the rna biomarker company putting people first to develop more effective drugs, supporting more targeted treatment decisions for better patient outcomes. genialis empowers biotech companies to get the most out of their data by interpreting data sets in a simple and intuitive way to identify new drug targets or disease biomarkers.
biomarker discovery framework
biotech companies can use the proprietary biomarker discovery framework to identify predictive gene signatures and stratify patients for clinical trials. the software platform also allows to predict side effects or to validate drug targets.
bottom of page